TR201908429T4 - Tiyotropyum içeren solunabilir ilaç. - Google Patents

Tiyotropyum içeren solunabilir ilaç. Download PDF

Info

Publication number
TR201908429T4
TR201908429T4 TR2019/08429T TR201908429T TR201908429T4 TR 201908429 T4 TR201908429 T4 TR 201908429T4 TR 2019/08429 T TR2019/08429 T TR 2019/08429T TR 201908429 T TR201908429 T TR 201908429T TR 201908429 T4 TR201908429 T4 TR 201908429T4
Authority
TR
Turkey
Prior art keywords
medicine containing
formulation
containing tiotropium
inhalable medicine
percentages
Prior art date
Application number
TR2019/08429T
Other languages
English (en)
Inventor
Zeng Xian-Ming
Original Assignee
Teva Branded Pharmaceutical Prod R & D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45813952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201908429(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Prod R & D Inc filed Critical Teva Branded Pharmaceutical Prod R & D Inc
Publication of TR201908429T4 publication Critical patent/TR201908429T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bu buluş, bir tiyotropyum tuzu, %12-20 etanol, %0,1-1,5 su, %0,05-0,10 sitrik asit (veya başka bir organik asit) ve bir HFA itici gazı içeren bir solüsyon formülasyonu ile ilgilidir, burada yüzdeler, formülasyonun toplam ağırlığına bağlı olarak ağırlıkça yüzdelerdir. Buluş, ayrıca formülasyonu ihtiva eden bir kutuyu içeren bir pMDI'yi sağlar.
TR2019/08429T 2011-12-19 2012-12-06 Tiyotropyum içeren solunabilir ilaç. TR201908429T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577315P 2011-12-19 2011-12-19
GBGB1200525.2A GB201200525D0 (en) 2011-12-19 2012-01-13 An inhalable medicament

Publications (1)

Publication Number Publication Date
TR201908429T4 true TR201908429T4 (tr) 2019-07-22

Family

ID=45813952

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08429T TR201908429T4 (tr) 2011-12-19 2012-12-06 Tiyotropyum içeren solunabilir ilaç.

Country Status (29)

Country Link
US (1) US9655969B2 (tr)
EP (3) EP3143998B1 (tr)
JP (1) JP5791166B2 (tr)
KR (2) KR20160111539A (tr)
CN (1) CN103998039A (tr)
AR (1) AR089302A1 (tr)
AU (1) AU2012358475B2 (tr)
BR (1) BR112014014535A2 (tr)
CA (1) CA2856047C (tr)
CY (1) CY1116142T1 (tr)
DK (3) DK3143998T3 (tr)
EA (1) EA028461B1 (tr)
ES (3) ES2728940T3 (tr)
GB (1) GB201200525D0 (tr)
HK (2) HK1200343A1 (tr)
HR (1) HRP20141176T1 (tr)
HU (2) HUE044647T2 (tr)
IL (1) IL232946A0 (tr)
MX (1) MX361925B (tr)
PL (3) PL2793886T3 (tr)
PT (1) PT2606891E (tr)
RS (1) RS53783B1 (tr)
SI (1) SI2606891T1 (tr)
SM (1) SMT201400192B (tr)
TR (1) TR201908429T4 (tr)
TW (1) TWI468187B (tr)
UY (1) UY34525A (tr)
WO (1) WO2013092237A1 (tr)
ZA (2) ZA201403041B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung
TR201911194T4 (tr) 2013-11-22 2019-08-21 Teva Branded Pharmaceutical Products R&D Inc Solunabilir bir ilaç.
HK1212903A1 (zh) * 2013-11-22 2016-06-24 Teva Branded Pharmaceutical Products R & D, Inc. 可吸入藥物
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2017075018A1 (en) * 2015-10-29 2017-05-04 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
CN114712337A (zh) * 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
WO2020006017A1 (en) * 2018-06-27 2020-01-02 3M Innovative Properties Company Tiotropium formulation and inhaler
EP4731184A1 (en) 2024-08-26 2026-04-29 Glenmark Pharmaceuticals Limited A pressurized inhalation composition of tiotropium
WO2026047392A1 (en) 2024-08-26 2026-03-05 Glenmark Specialty S.A. A pressurized inhalation composition of tiotropium

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
NZ246046A (en) 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
GB2264238A (en) 1992-05-29 1993-08-25 Norton Healthcare Ltd Medicament inhalor device
ATE177941T1 (de) 1992-12-09 1999-04-15 Boehringer Ingelheim Pharma Stabilisierte medizinische aerosollösungen
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
JP4691298B2 (ja) 1999-10-12 2011-06-01 科研製薬株式会社 粉末吸入用製剤及びその製造方法
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US6553988B1 (en) 2000-06-09 2003-04-29 Norton Healthcare, Inc. Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
WO2002030928A1 (de) 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
TR200402367T4 (tr) 2000-10-12 2004-12-21 Boehringer Ingelheim Pharma Gmbh& Co.Kg Yeni tiotropyum içeren inhalasyon tozları
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20030070679A1 (en) 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
ME00412B (me) 2001-06-22 2011-10-10 Boehringer Ingelheim Pharma Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10214263A1 (de) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
CA2510043A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing hfc solution formulations
US20050058606A1 (en) 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
CA2576410A1 (en) 2003-09-18 2006-03-31 Norton Healthcare Ltd. Particles
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
ME00349B (me) 2003-11-03 2011-05-10 Boehringer Ingelheim Int Novi kristalni anhidrat sa antiholinergij skim dejstvom
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
US20060079544A1 (en) 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
EP1850831B1 (en) * 2005-02-25 2015-12-02 CHIESI FARMACEUTICI S.p.A. Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
JP2008540367A (ja) 2005-05-02 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
NZ564697A (en) 2005-06-15 2010-04-30 Boehringer Ingelheim Int Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
EP1915158A1 (en) 2005-08-06 2008-04-30 Boehringer Ingelheim International GmbH Use of tiotropium salts in the treatment of severe persistant asthma
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US8163913B2 (en) 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
EP1923393A1 (en) 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
CA2750711C (en) 2009-01-26 2015-07-07 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
KR20120109504A (ko) * 2009-11-17 2012-10-08 시플라 리미티드 흡입 용액
PT2627386E (pt) 2010-10-12 2015-06-11 Ivax Pharmaceuticals Ireland Dispositivo de pulverização nasal
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung

Also Published As

Publication number Publication date
US9655969B2 (en) 2017-05-23
EP3143998B1 (en) 2019-05-22
MX2014007357A (es) 2014-08-21
ZA201403041B (en) 2015-11-25
TWI468187B (zh) 2015-01-11
CA2856047C (en) 2017-01-03
ES2526685T3 (es) 2015-01-14
KR20160111539A (ko) 2016-09-26
JP2015500224A (ja) 2015-01-05
DK3143998T3 (da) 2019-06-17
CN103998039A (zh) 2014-08-20
NZ624161A (en) 2015-08-28
EP2606891A1 (en) 2013-06-26
PL2606891T3 (pl) 2015-07-31
SMT201400192B (it) 2015-03-05
EP2793886B1 (en) 2016-08-24
GB201200525D0 (en) 2012-02-29
TW201332587A (zh) 2013-08-16
EP3143998A1 (en) 2017-03-22
AU2012358475B2 (en) 2015-08-20
CY1116142T1 (el) 2017-03-15
IL232946A0 (en) 2014-07-31
DK2793886T3 (en) 2016-12-05
ES2728940T3 (es) 2019-10-29
UY34525A (es) 2014-07-31
KR20140097481A (ko) 2014-08-06
SI2606891T1 (sl) 2015-04-30
PT2606891E (pt) 2015-01-05
MX361925B (es) 2018-12-19
EA201491206A1 (ru) 2014-12-30
HUE044647T2 (hu) 2019-11-28
EA028461B1 (ru) 2017-11-30
KR101670564B1 (ko) 2016-10-28
EP2793886A1 (en) 2014-10-29
DK2606891T3 (en) 2015-01-05
HUE030983T2 (en) 2017-06-28
JP5791166B2 (ja) 2015-10-07
PL3143998T3 (pl) 2019-09-30
RS53783B1 (sr) 2015-06-30
PL2793886T3 (pl) 2017-06-30
ES2602314T3 (es) 2017-02-20
AR089302A1 (es) 2014-08-13
EP2606891B1 (en) 2014-11-05
CA2856047A1 (en) 2013-06-27
WO2013092237A1 (en) 2013-06-27
HK1198512A1 (en) 2015-05-15
HRP20141176T1 (hr) 2015-03-13
HK1200343A1 (en) 2015-08-07
US20140348758A1 (en) 2014-11-27
BR112014014535A2 (pt) 2017-06-13
AU2012358475A1 (en) 2014-05-22
ZA201501986B (en) 2016-10-26
AU2012358475A8 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
TR201908429T4 (tr) Tiyotropyum içeren solunabilir ilaç.
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2013011774A (es) Derivados de acido 3-fenilpropionico ramificados y su uso.
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EA201270216A1 (ru) Фармацевтический состав
MX339033B (es) Derivados de acido antranilico.
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112013032758A2 (pt) derivados de n-oxi-pirazolo-triazepino-diona
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
CA2920410C (en) Thienopiperidine derivative and use thereof
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
CO6382113A2 (es) Compuestos quimicos
UY32496A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-aril-metil]-heterobenzamida, su preparación y su aplicación en terapéutica.
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
TR201911194T4 (tr) Solunabilir bir ilaç.
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
TH159388A (th) สารประกอบแมคโครไซคลิคและวิธีการผลิตของมัน